OpenArc Corporate Advisory’s AstraZeneca AZN Stock Holding History

OpenArc Corporate Advisory’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.26M	Buy	27,729 +1,078	+4%	+$203K	0.06%	154
2026 Q1	$5.26M	Buy	26,651 +12,590	+90%	+$2.43M	0.08%	144
2025 Q4	$2.59M	Buy	+14,061	New	+$2.47M	0.04%	201

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OpenArc Corporate Advisory's AZN Position: Q2 2026 in Review

OpenArc Corporate Advisory increased its AstraZeneca (AZN) stake by 4% in Q2 2026, buying an estimated $203K and bringing the position to 27,729 shares worth $5.26M. The position accounts for 0.06% of the portfolio, ranked #154.

OpenArc Corporate Advisory first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

OpenArc Corporate Advisory held 27,729 shares of AstraZeneca worth $5.26M as of Q2 2026.
OpenArc Corporate Advisory bought 1,078 AstraZeneca shares in Q2 2026, an estimated $203K.
AstraZeneca made up 0.06% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #154 holding.
OpenArc Corporate Advisory first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.